Immix Biopharma (IMMX) Capital Expenditures (2021 - 2026)

Immix Biopharma has reported Capital Expenditures for 5 years, with the latest figure at $32486.0 in Q1 2026.

• Quarterly Capital Expenditures fell 52.02% year-over-year to $32486.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $697698.0 (down 26.05% YoY) and the FY2025 annual result came in at $732925.0, down 37.77% from the prior year.
• Capital Expenditures slipped to $32486.0 in Q1 2026 per IMMX's latest filing, from $165126.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $507151.0 in Q4 2024 and troughed at $13177.0 in Q4 2023.
• A 4-year average of $195626.8 and a median of $146378.0 in 2025 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2024 and 2025: Capital Expenditures soared 3748.76% in 2024, then sank 77.57% in 2025.
• Over 4 years, Capital Expenditures stood at $13177.0 in 2023, then jumped by 3748.76% to $507151.0 in 2024, then slumped by 67.44% to $165126.0 in 2025, then sank by 80.33% to $32486.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $32486.0, $165126.0, and $372456.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.